Immunovant, Inc. - Common Stock (NQ:IMVT)

33.65 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Immunovant, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Immunovant (IMVT) Q1 2027 Earnings Call Transcript ↗

August 13, 2026

CEO signals multiple pivotal data readouts ahead as cash runway supports IMVT-1402 development.

Via The Motley Fool

Topics Earnings

Immunovant Q1 Earnings Call Highlights ↗

August 06, 2026

Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple...

Via MarketBeat

Topics Earnings

This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗

May 24, 2026

Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions.

Via The Motley Fool

Topics Regulatory Compliance

Immunovant Inc (NASDAQ:IMVT) Surges 26% Pre-Market on Strong IMVT-1402 Clinical Data Despite Wider Q4 Loss ↗

May 20, 2026

Via Chartmill

Immunovant Inc (NASDAQ:IMVT) Reports Q3 FY2026 Results, Beats EPS Estimates and Provides Key Clinical Updates ↗

February 06, 2026

Via Chartmill

This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗

May 24, 2026

This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.

Via The Motley Fool

Topics Regulatory Compliance

What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗

May 23, 2026

This biotech firm develops therapies for urothelial cancers, leveraging proprietary delivery technology and a growing clinical pipeline.

Via The Motley Fool

Topics Regulatory Compliance

Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗

May 23, 2026

Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation.

Via The Motley Fool

These Analysts Increase Their Forecasts On Immunovant After Q4 Results ↗

May 21, 2026

Immunovant (NASDAQ:IMVT) reported a Q4 loss of 73 cents/share, missing estimates of 60 cents. R&D expenses rose to $142.3 million. Analysts adjust price targets.

Via Benzinga

Top movers in Wednesday's session ↗

May 20, 2026

Via Chartmill

Immunovant Stock Surges Despite Disappointing Earnings Miss ↗

May 20, 2026

Immunovant Inc (NASDAQ: IMVT) shares are trading higher Wednesday despite posting a wider-than-expected fourth‑quarter loss.

Via Benzinga

Keep an eye on the top gainers and losers in Wednesday's session. ↗

May 20, 2026

Via Chartmill

Traders are paying attention to the gapping stocks in Wednesday's session. ↗

May 20, 2026

Via Chartmill

Immunovant Q4 Earnings Call Highlights ↗

May 20, 2026

Roivant executives used the company’s fourth-quarter and fiscal-year earnings call to highlight new clinical data from its development portfolio, upcoming readouts and its strengthened balance sheet...

Via MarketBeat

Topics Earnings

Stay updated with the stocks that are on the move in today's pre-market session. ↗

May 20, 2026

Via Chartmill

Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗

May 18, 2026

This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships.

Via The Motley Fool

Topics Regulatory Compliance

Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗

May 18, 2026

Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.

Via The Motley Fool

Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗

May 18, 2026

Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases.

Via The Motley Fool

Topics ETFs Regulatory Compliance

Amgen’s Subcutaneous TEPEZZA Data Sets New Gold Standard for Thyroid Eye Disease Treatment

April 13, 2026

THOUSAND OAKS, Calif. – In a move that significantly strengthens its hold on the thyroid eye disease (TED) market, Amgen (NASDAQ: AMGN) recently announced pivotal Phase 3 topline results for its...

Via MarketMinute

Roivant and Immunovant Solidify Market Leadership as Brepocitinib and FcRn Programs Hit Critical Clinical Milestones

April 02, 2026

The biotechnology sector witnessed a seismic shift this week as Roivant Sciences (Nasdaq: ROIV) and its subsidiary Immunovant (Nasdaq: IMVT) reported a series of clinical and regulatory updates that...

Via MarketMinute

Topics Intellectual Property

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? ↗

March 15, 2026

This clinical-stage biotech develops antibody therapies targeting autoimmune diseases, with a lead candidate in Phase II trials.

Via The Motley Fool

Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough

March 12, 2026

Date: March 12, 2026 Introduction Dianthus Therapeutics (NASDAQ: DNTH) has become the center of Wall Street’s attention today, with its share price surging 19.4% in early trading following a pivotal...

Via Finterra

Topics Economy

Air Taxi Stock Archer Aviation Draws $22.5 Million Institutional Buy. Here's What Investors Should Know ↗

March 11, 2026

Archer Aviation designs and manufactures electric aircraft for urban passenger transport, targeting the growing urban air mobility market.

Via The Motley Fool

Topics Regulatory Compliance

Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish ↗

March 11, 2026

This biotech specializes in antibody therapies for autoimmune diseases, with its lead candidate progressing through trials.

Via The Motley Fool

Truth Social Stock Down 50% as One Investor Sells Off Nearly 800,000 Shares ↗

March 11, 2026

This digital media firm operates Truth Social, a platform delivering internet content and information services to online audiences.

Via The Motley Fool

Topics Government

Argenx (ARGX) 2026 Feature: The Anatomy of a Biotech Powerhouse Transitioning to Profitability

February 26, 2026

As of February 26, 2026, the biotechnology sector is witnessing a historic maturation. For years, the industry narrative was dominated by high-burn, pre-revenue innovators searching for a "blockbuster"...

Via Finterra

Topics Earnings Economy Intellectual Property

Immunovant (IMVT) Q2 2025 Earnings Call Transcript ↗

February 06, 2026

Immunovant (IMVT) Q2 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model

February 06, 2026

As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a...

Via Finterra

Topics ETFs Economy Initial Public Offering

Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? ↗

December 18, 2025

Focused on monoclonal antibody therapies for autoimmune diseases, this biotech just reported a significant insider buy in public filings.

Via The Motley Fool

Topics Regulatory Compliance

Immunovant Inc (NASDAQ:IMVT) Stock Falls 10% on Q2 FY2026 Earnings and Corporate Updates ↗

November 10, 2025

Immunovant stock drops 10% despite meeting Q2 FY2026 earnings estimates. The sell-off is driven by investor reaction to clinical pipeline updates for its anti-FcRn therapies.

Via Chartmill

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.